Alvaro Urzúa

Alvaro Urzúa

Auto-generated profile, based on publicly available information

Alvaro Urzúa

Unidad de Gastroenterología y Trasplante Hepático, Hospital Clínico, Universidad de Chile. Santiago, Chile

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Hepatology
Verified
Journal Article
Closed access
CECumali Efe
Cumali Efe
AKAnand V Kulkarni
Anand V Kulkarni
BBBenedetta Terziroli Beretta‐Piccoli
Benedetta Terziroli Beretta‐Piccoli
BMBianca Magro
Bianca Magro
ASAlbert Stättermayer
Albert Stättermayer
SWStaffan Wahlin
Staffan Wahlin

13 March 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
CECumali Efe
Cumali Efe
RDRenumathy Dhanasekaran
Renumathy Dhanasekaran
CLCraig Lammert
Craig Lammert
BEBerat Ebik
Berat Ebik
FTFatima Higuera‐De la Tijera
Fatima Higuera‐De la Tijera
SWStaffan Wahlin
Staffan Wahlin

Verified
Journal Article
Open access
PDF file
AZAlejandra Zazueta
Alejandra Zazueta
Lucía Valenzuela-PérezLucía Valenzuela-Pérez
Lucía Valenzuela-Pérez
Nicolas Ortiz-LópezNicolas Ortiz-López
Nicolas Ortiz-López
AParaceli pinto
araceli pinto
VTVerónica Torres
Verónica Torres
CBCaroll Jenny Beltrán
Caroll Jenny Beltrán
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex disorder whose prevalence is rapidly growing in South America. The disturbances in the microbiota–gut–liver axis impact the liver damaging processes toward fibrosis. Gut microbiota status is shaped by dietary and lifestyle factors, depending on geographic location. We aimed to identify microbial signatures in a group of Chilean MASLD patients. Forty subjects were recruited, including healthy controls (HCs), overweight/obese subjects (Ow/Ob), patients with MASLD without fibrosis (MASLD/F−), and MASLD with fibrosis (MASLD/F+). Both MASLD and fibrosis were detected through elastography and/or biopsy, and fecal microbiota were analyzed through deep sequencing. Despite no differences in α- and β-diversity among all groups, a higher abundance of Bilophila and a lower presence of Defluviitaleaceae, Lachnospiraceae ND3007, and Coprobacter was found in MASLD/F− and MASLD/F+, compared to HC. Ruminococcaceae UCG-013 and Sellimonas were more abundant in MASLD/F+ than in Ow/Ob; both significantly differed between MASLD/F− and MASLD/F+, compared to HC. Significant positive correlations were observed between liver stiffness and Bifidobacterium, Prevotella, Sarcina, and Acidaminococcus abundance. Our results show that MASLD is associated with changes in bacterial taxa that are known to be involved in bile acid metabolism and SCFA production, with some of them being more specifically linked to fibrosis.

26 September 2022 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
ÁUÁlvaro Urzúa
Álvaro Urzúa
CPCarolina Pizarro
Carolina Pizarro
AGAbraham I. Gajardo
Abraham I. Gajardo
RPRafael Poniachik
Rafael Poniachik
CPClaudia Pavez
Claudia Pavez
JPJaime Poniachik
Jaime Poniachik
Introduction. Autoimmune hepatitis (AIH) is a chronic liver disease with a relevant inflammatory component and an unknown etiology. Evidence for clinical characteristics and risk factors in large cohorts of patients with acute AIH (AAIH) is lacking. We clinically characterized patients with AAIH, the prevalence of a combined adverse outcome (death or liver transplantation (LT)), and its risk factors. Methods. A retrospective study of adult patients diagnosed with AAIH at three centers (Santiago, Chile; 2000–2018) was conducted. Clinical and laboratory characteristics were obtained. A liver biopsy was performed for all patients. Descriptive statistics and logistic regression models were used. Results. A total of 126 patients were admitted; 77% were female, 33 (26.2%) had a severe presentation, and 14 (11.1%) had a fulminant presentation. Overall, 24 patients (19.0%) lacked typical autoantibodies, and 26.2% had immunoglobulin G levels in the normal range. The most frequent histological findings were plasma cells (86.5%), interface hepatitis (81.7%), and chronic hepatitis (81.0%). Rosettes were uncommon (35.6%). Advanced fibrosis was present in 27% of patients. Combined adverse outcomes occurred in 7.9% of cases, all fulminant with histological cholestasis. Alkaline phosphatase, bilirubin, and prothrombin less than 50% were independent risk factors for in-hospital death or LT ( value <0.05). Although corticosteroid treatment was associated with better outcomes (OR 0.095, value = 0.013), more severe patients were less likely to receive this therapy. Discussion. In this large cohort of patients with AAIH, clinical characteristics differ from those reported in patients with chronic AIH. Fulminant hepatitis, histological cholestasis, alkaline phosphatase, bilirubin, and prothrombin were associated with death/LT.

6 May 2024 in Annals of Hepatology
Verified
Journal Article
Open access
LVLuis Vega
Luis Vega
DSDaniela Simian
Daniela Simian
AGAbraham I. Gajardo
Abraham I. Gajardo
MSMarcelo Salinas
Marcelo Salinas
AUAndrea Urra
Andrea Urra
JPJaime Poniachik
Jaime Poniachik
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis. This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021-Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann-Whitney U test, and logistic regression models were used (p<0.05). The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p=0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06-3.04; p=0.029). MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.

16 June 2023 in Annals of Hepatology
Verified
Journal Article
Open access
CBCarlos Benítez
Carlos Benítez
JAJorge Arnold
Jorge Arnold
VCVerónica Cambindo
Verónica Cambindo
FSFernanda Schoenfeldt
Fernanda Schoenfeldt
ACAlejandra Cancino
Alejandra Cancino
VPVicente Pizarro
Vicente Pizarro
Acute-on-chronic liver failure (ACLF) is associated with reduced short-term survival, and liver transplantation is frequently the only therapeutic option. Nonetheless, the post-transplantation prognosis seems to be worse in ACLF patients. The databases of two university centers were retrospectively evaluated, and adult patients with cirrhosis who underwent transplantation between 2013 and 2020 were included. One-year survival of patients with ACLF was compared to that of patients without ACLF. Variables associated with mortality were identified. A total of 428 patients were evaluated, and 303 met the inclusion criteria; 57.1% were male, the mean age was 57.1 ± 10.2 years, 75 patients had ACLF, and 228 did not. The main etiologies of ACLF were NASH (36.6%), alcoholic liver disease (13.9%), primary biliary cholangitis (8.6%) and autoimmune hepatitis (7.9%). Mechanical ventilation, renal replacement therapy, the use of vasopressors and the requirement of blood product transfusion during liver transplantation were significantly more frequent in ACLF patients. Among those recipients without and with ACLF, survival at 1, 3 and 5 years was 91.2% vs. 74.7%, 89.1% vs. 72.6% and 88.3% vs. 72.6%, respectively (p=0.001). Among pre-transplantation variables, only the presence of ACLF was independently associated with survival (HR 3.2, 95% CI: 1.46-7.11). Post-transplantation variables independently associated with survival were renal replacement therapy (HR 2.8, 95% CI: 1.1-6.8) and fungal infections (HR 3.26, 95% CI: 1.07-9.9). ACLF is an independent predictor of one-year post-transplantation survival. Importantly, transplant recipients with ACLF require the use of more resources than patients without ACLF.